MedMira Files Pre-IDE with FDA for New Rapid HIV Test to Meet Demand for Increased Routine Screening in the US

MedMira Files Pre-IDE with FDA for New Rapid HIV Test to Meet Demand for 
Increased Routine Screening in the US 
Company commends USPSTF on new recommendations for routine HIV screening at 
the point-of-care 
HALIFAX, Nov. 30, 2012 /CNW/ - MedMira Inc., (MedMira) (TSXV: MIR), a 
developer of rapid diagnostic technology and solutions, commends the U.S. 
Preventive Services Task Force (USPSTF) on its new guidelines calling for 
routine HIV screening of all people aged 15-65 and all pregnant women in the 
United States during the normal course of medical care. 
The new guidelines will significantly increase the number of people being 
screened for HIV, as previous recommendations and insurance policies only 
covered routine testing for individuals considered at high risk.According to 
the US Centers for Disease Control and Prevention (CDC), approximately 1 in 5 
of the 1.2 million people in the US living with HIV do not know that they are 
infected.The new recommendations, which are available until December 17, 
2012 for public comment, are in line with the CDC's recommendations for 
routine HIV testing for people 13 years of age or older. 
"We believe that the USPSTF's new recommendations on routine HIV testing will 
have a significant influence on the early treatment of those individuals 
unaware of their HIV infection, as well as preventing the further spread of 
the disease," said Hermes Chan, CEO, MedMira Inc."As HIV testing becomes 
part of routine visits to doctor's offices and convenience care clinics, we 
expect to see an increased demand for high quality, efficient, rapid tests 
designed for use at the point-of-care.With this in mind, we are bringing a 
whole blood version of our Reveal G3 rapid HIV test to US healthcare 
providers.Our technology enables a 3 minute procedure and instant results 
for HIV screening, and a highly cost-effective diagnostic tool for healthcare 
providers and their patients." 
Earlier this month, MedMira submitted a pre-IDE (Investigational Device 
Exemption) information package to the U.S. Food and Drug Administration (FDA) 
for a whole blood rapid HIV test.The Company currently sells its Reveal G3 
Rapid HIV-1 Antibody Test in the US for use in laboratories and 
hospitals.The new version will be aimed at physician offices, convenience 
care clinics, mobile testing, and large scale public health programs where 
whole blood specimens are preferred and much of the new routine HIV screening 
will take place. 
About the U.S. Preventive Services Task Force (USPSTF) 
The USPSTF is an independent group of national experts in prevention and 
evidence-based medicine that works to improve the health of all Americans by 
making evidence-based recommendations about clinical preventative services, 
such as screenings, counseling services, and preventative medications.USPSTF 
recommendations have formed the basis of the clinical standards for many 
professional societies, health organizations, and medical quality review 
groups.To learn more about USPSTF visit 
About MedMira 
MedMira is a leading developer and manufacturer of flow-through rapid 
diagnostics and technologies. MedMira is the only Canadian company to be 
awarded US Army contracts for the development of rapid tests for HIV and 
Hepatitis viruses.The Company's testing solutions provide hospitals, labs, 
clinics and individuals with reliable, rapid diagnosis for diseases such as 
HIV and hepatitis C in just three minutes. The Company's tests are sold under 
the Reveal®, Multiplo™ and Miriad brands in global markets. MedMira is 
located in Halifax, Nova Scotia, Canada. 
This news release contains forward-looking statements, including statements 
relating to growth in the Company's business, earnings and profitability, and 
trends in demand for the Company's products, which involve risk and 
uncertainties and reflect the Company's current expectation regarding future 
events including statements regarding possible future growth and new business 
opportunities.Actual events could materially differ from those projected 
herein and depend on a number of factors including, but not limited to, 
changing market conditions, successful and timely completion of clinical 
studies, uncertainties related to the regulatory approval process, 
establishment of corporate alliances and other risks detailed from time to 
time in the company quarterly filings. 
Neither TSX Venture Exchange nor its Regulation Services Provider (as that 
term is defined in the policies of the TSX Venture Exchange) accepts 
responsibility for the adequacy or accuracy of this release. 
MedMira Contact: Andrea Young, Corporate Communications Tel: 902-450-1588 
To view this news release in HTML formatting, please use the following URL: 
ST: Nova Scotia
-0- Nov/30/2012 14:09 GMT
Press spacebar to pause and continue. Press esc to stop.